ES2111891T3 - Empleo de l-carnitina o acil l-carnitinas y valproato para tratar trastornos epilepticos. - Google Patents

Empleo de l-carnitina o acil l-carnitinas y valproato para tratar trastornos epilepticos.

Info

Publication number
ES2111891T3
ES2111891T3 ES94830306T ES94830306T ES2111891T3 ES 2111891 T3 ES2111891 T3 ES 2111891T3 ES 94830306 T ES94830306 T ES 94830306T ES 94830306 T ES94830306 T ES 94830306T ES 2111891 T3 ES2111891 T3 ES 2111891T3
Authority
ES
Spain
Prior art keywords
acil
carnitines
valproate
carnitine
epileptic disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94830306T
Other languages
English (en)
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2111891T3 publication Critical patent/ES2111891T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

EL USO COORDINADO DE L-CARNITINA O ACILO L-CARNITINAS Y VALPROATO PERMITE UNA DISMINUCION CONSIDERABLE EN LA FRECUENCIA DEL AGARROTAMIENTO, SEGUN SE HA OBSERVADO EN PACIENTES EPILEPTICOS.
ES94830306T 1993-07-06 1994-06-22 Empleo de l-carnitina o acil l-carnitinas y valproato para tratar trastornos epilepticos. Expired - Lifetime ES2111891T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM930441A IT1261808B (it) 1993-07-06 1993-07-06 Impiego di l-carnitina o acido l-carnitine e valproato nel trattamentodei disosrdini convulsivi

Publications (1)

Publication Number Publication Date
ES2111891T3 true ES2111891T3 (es) 1998-03-16

Family

ID=11401844

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94830306T Expired - Lifetime ES2111891T3 (es) 1993-07-06 1994-06-22 Empleo de l-carnitina o acil l-carnitinas y valproato para tratar trastornos epilepticos.

Country Status (8)

Country Link
EP (1) EP0637449B1 (es)
AT (1) ATE161718T1 (es)
DE (1) DE69407684T2 (es)
DK (1) DK0637449T3 (es)
ES (1) ES2111891T3 (es)
GR (1) GR3025845T3 (es)
HK (1) HK1005771A1 (es)
IT (1) IT1261808B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9709627A (pt) * 1996-05-31 1999-08-10 Sigma Tau Ind Farmaceuti Sais n o-higroscópicos estáveis de L(-)carnitina e alcanoílal(-)carnitinas um processo para sua preparação e composições sólidas oralmente administráveis contendo tais sais
EP0972516A1 (en) * 1998-06-25 2000-01-19 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Gastro-intestinal adverse effect-free composition comprising an L-carnitine replacement.
ITRM20010030A1 (it) * 2001-01-23 2002-07-23 Aldo Fassi Sali di carnitine utili come integratori dietetici/nutrizionali o come farmaci, composizioni che li contengono e procedimenti per la loro pr
GB0307860D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US7456216B2 (en) * 2007-03-19 2008-11-25 Biolink Life Sciences, Inc. Methods for the preparation and formulation of l-carnitine valproate salts
US20110015267A1 (en) * 2009-07-20 2011-01-20 Deanna Jean Nelson Methods for the preparation and use of aqueous solutions of magnesium valproate hydrate and l-carnitine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3726945A1 (de) * 1987-08-13 1989-02-23 Dietl Hans L-carnitinderivate der valproinsaeure und diese enthaltende arzneimittel

Also Published As

Publication number Publication date
ATE161718T1 (de) 1998-01-15
EP0637449A1 (en) 1995-02-08
DK0637449T3 (da) 1998-05-25
EP0637449B1 (en) 1998-01-07
HK1005771A1 (en) 1999-01-22
ITRM930441A0 (it) 1993-07-06
DE69407684T2 (de) 1998-04-30
GR3025845T3 (en) 1998-04-30
DE69407684D1 (de) 1998-02-12
ITRM930441A1 (it) 1995-01-06
IT1261808B (it) 1996-06-03

Similar Documents

Publication Publication Date Title
ES2071484T3 (es) Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
AR037109A1 (es) Uso de flibanserina
EP0386997A3 (en) Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation, and as immunosuppressants
CA2208018A1 (en) Sulfonamides
DK1296671T3 (da) Gabapentinanaloger til sövnforstyrrelser
CL2008003941A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden compulsivo obsesivo.
ES2089687T3 (es) 4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa.
MXPA03003774A (es) Derivados de acilo y sulfonilo de 2-(trans-1, 4-diaminociclohexil)-purinas 6,9-disubstituidas y sus uso como agentes antiproliferativos.
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
SE9701161D0 (sv) New use I
ES2111891T3 (es) Empleo de l-carnitina o acil l-carnitinas y valproato para tratar trastornos epilepticos.
ES2175006T3 (es) N-(pirimidinil)-benzosulfonamidas como medicamentos.
ES2191206T3 (es) Nueva utilizacion de la creatina.
ES2174101T3 (es) Articulo absorbente con elemento absorbente estabilizante.
ES2085051T3 (es) Usos de 1,1,1,3,3,3-hexafluoropropano.
AR023452A1 (es) Utilizacion del osanetant para preparacion de medicamentos utiles en el tratamiento de los trastornos del humor
ES2188742T3 (es) Trapidil para uso en la terapia de cuadros patologicos influenciables por la inmunomodulacion.
MY116362A (en) Use of selegiline for the treatment of epileptic disorders
ES2183205T3 (es) Hcg y derivados en calidad de inhibidores de melaloproteasas de la matriz.
MX9203205A (es) Novedosos acidos dimetilamino-hidroxi-alcan-difosfonicos y sales de los mismos, en procedimiento de produccion y composiciones farmaceuticas relacionadas.
ES2163450T3 (es) Utilizacion de benzidamina en el tratamiento de estados patologicos causados por tnf.
RU96119673A (ru) Способ лечения болевого синдрома
ES2174272T3 (es) Utilizacion del (r)-verapamilo como medicamento para el tratamiento de la angina.
RU97107034A (ru) Способ лечения синдрома сухого глаза
EA200200750A1 (ru) Новое терапевтическое применение еноксапарина

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 637449

Country of ref document: ES